Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Financial Strength

8/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	216.88
Equity-to-Asset	0.92
Debt-to-Equity	0.01
Debt-to-EBITDA	-0.01
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	0.6	Distress Grey Safe
Beneish M-Score	4.65	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

1/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-59
	3-Year Book Growth Rate	-27.9

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	52.65
	9-Day RSI	49.14
	14-Day RSI	46.51
	6-1 Month Momentum %	-48.73
	12-1 Month Momentum %	-76.37

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	12.22
	Quick Ratio	12.22
	Cash Ratio	11.6
	Days Payable	1129.09

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1
	Shareholder Yield %	1.04

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	96.49
	Operating Margin %	-558.5
	Net Margin %	-552.52
	FCF Margin %	-466.77
	ROE %	-56.67
	ROA %	-51.31
	ROIC %	-1194.67
	ROC (Joel Greenblatt) %	-6194.2
	ROCE %	-57.23
	Years of Profitability over Past 10-Year	1

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	7.36
	PB Ratio	0.92
	Price-to-Tangible-Book	0.92
	EV-to-EBIT	0.12
	EV-to-EBITDA	0.12
	EV-to-Forward-EBITDA	-0.02
	EV-to-Revenue	-0.67
	EV-to-Forward-Revenue	0.23
	EV-to-FCF	0.12
	Price-to-Net-Current-Asset-Value	0.94
	Price-to-Net-Cash	0.99
	Earnings Yield (Greenblatt) %	833.33
	FCF Yield %	-65.28

GF Value: $174.25

SAGE

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with SAGE. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.